REICIN ALISE 4

What Happened
Alise Reicin, CEO of Tectonic Therapeutic (TECX), reported a purchase of 2,500 shares on February 11, 2026. The shares were acquired at a weighted average price of $21.10 per share for a total cost of approximately $52,750. The Form 4 marks the transaction type as "P" (purchase), indicating an open-market or private purchase.

Key Details

• Transaction date: 2026-02-11 (reported on Form 4 filed 2026-02-12) — filing appears timely.
• Price: weighted average $21.10; individual trades ranged from $21.02 to $21.15 (footnote).
• Shares acquired: 2,500; total reported value ≈ $52,750.
• Shares held after transaction: not disclosed in the provided filing.
• Footnotes of note:
  • F1: Price is a weighted average; the reporting person will provide a breakdown of the number of shares bought at each price upon request.
  • F2: These shares are held by the Reicin-Boiarsky Family Trust; the CEO’s spouse is a co-trustee. The reporting person may be deemed to share voting/dispositive power but disclaims beneficial ownership except to the extent of any pecuniary interest.

Context
Purchases by company insiders are often viewed as a positive signal because they increase the insider’s stake, but they do not prove future stock performance. This filing documents a straightforward purchase (code P) rather than an option exercise, gift, or award. No late-filing flag was apparent given the transaction and filing dates.